Carlsmed (CARL) had its price target lowered by Truist Financial Corporation from $20.00 to $18.00. They now have a "buy" rating on the stock.
Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
Carlsmed (CARL) had its price target lowered by The Goldman Sachs Group, Inc. from $19.00 to $17.00. They now have a "buy" rating on the stock.
Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference
Carlsmed (CARL) was upgraded by Zacks Research from "strong sell" to "hold".